Scope
This document outlines laboratory testing criteria and specimens to be collected for symptomatic persons with history of exposure to heater-cooler units during cardiothoracic heart surgery performed from November 1 st , 2011 onward.
Background
A recent outbreak of Mycobacterium chimaera has been detected globally in patients who have undergone cardiothoracic heart surgery while in the presence of contaminated heater-cooler units. At this point in time, 52 cases of non-tuberculosis Mycobacterium (NTM) have been detected in Europe, and 2 within Canada (11).
There are many areas of uncertainty with respect to: 1) the magnitude and factors affecting infection risk, 2) clinical presentations of disease and 3) ideal management of devices.
RAPID COMMUNICATION
At this time the risk to patients is thought to be low as evidenced by small number of cases reported globally. Risk estimates will be supplied as more information becomes available.
The Canadian Public Health Laboratory Network and its partners are working to support the laboratory response through the production of these interim recommendations.
This guidance document will focus on 1) defining patients at risk to establish criteria for testing and 2) recommendations related to the sample collection and testing for detection of M. chimaera in patients.
Clinical presentations * associated with post-operative non-tuberculous Mycobacterium infection
The majority of patients present three months to five years (median 18 months) after the index surgery, with symptoms of fever, fatigue, shortness of breath, night sweats, joint or muscle pain and unexplained weight loss (1, 3, 7) . Cardiac manifestations include prosthetic valve endocarditis (PVE), prosthetic vascular graft infection (PVGI), paravalvular abscess, and pseudo and mycotic aneurysms (7.10). Extracardiac manifestations include bone infection (osteomyelitis, spondylodiscitis), sternotomy wound infection, mediastinitis, hepatitis, and bloodstream infection (BSI) (3, 7, 10) . Ocular manifestations due to emboli (panuveitis, multifocal chorioiditis, chorioretinitis) are observed in approximately 50% of patients (3) . Immunologic manifestations include arthritis, cerebral vasculitis, pneumonitis, myocarditis, granulomatous nephritis) (7, 10) . Splenomegaly is observed in approximately 80% of cases (3) as well as bone marrow involvement with cytopenia. Recent recommendations have raised awareness for granulomatous diseases, particularly those that resemble sarcoidosis (11). There have been case reports of M. chimaera patients who were initially diagnosed with sarcoidosis.
Patient testing criteria Criteria 1: Risk exposure
Patients must have had cardiothoracicsurgery in the past. Due to the prolonged incubation time, patients who have had surgery from November of 2011 onward would be considered to meet this criterion.
Caveat: Some isolated reports involve patients without cardiothoracic surgery, but in a room with an active heater-cooler unit on standby. While these patients are not routinely felt to be at risk, such patients could be considered for NTM testing if a compatible clinical syndrome was present (see below).
*
Prior presentations: Published literature from Germany (5 cases) 2 , Switzerland (6 cases) 1 and the United Kingdom (17 cases) 9 demonstrate that the majority of patients presented with endocarditis, paravalvular abscess, site infection or bacteremia associated with artery bypass graft, valve replacement or repair. Common accompanying signs and symptoms were fatigue, fever, hepatitis, renal insufficiency, splenomegaly and pancytopenia.
Criteria 2: Compatible clinical syndrome
Overall patients tend to present with non-specific symptoms, making the distinction of NTM infection from other, more common causes of these symptoms difficult. To that end, a compatible syndrome is defined as presence of:
• Constitutional: recurrent or prolonged fever, fatigue, shortness of breath, weight loss, night sweats, joint or muscle pain
if present prior to surgery, must have significantly worsened following surgery AND symptoms should have been present ≥ three weeks. Persistence of these non-specific symptoms beyond three weeks helps to eliminate other infections that generally are diagnosed or resolved within that time span. In the absence of a diagnosis (both infectious and non-infectious) patients with unexplained symptoms should be investigated for possible M. chimaera infection.
Important testing considerations
• Asymptomatic individuals who have undergone cardiothoracic surgery should not undergo testing for M. chimaera, based on current evidence. • It may be impractical to wait ≥3 weeks, either due to severe illness or when patient follow-up will be complex due to frailty or geographic access. Under these exceptional circumstances, one can consider proceeding to NTM testing without waiting.
Specimens
The following specimens should be submitted for mycobacterial cultures from eligible patients, as identified by the testing recommendations:
Clinical samples from sterile sites ( Table 1) , such as, but not restricted to, blood, purulent drainage, or fresh tissue should be sent for mycobacterial culture and acid fast bacilli (AFB) smear with accompanying requisition (Appendix 1: Links to local laboratory services). Please note, M. chimaera is a slow growing organism and detection through culture can take up to 6-8 weeks incubation. If it is early in the infection, M. chimaera may not be detected.
Positive cultures identified as M. avium-intracellulare complex microorganisms must be sent forward to a reference laboratory for 16S (or alternative such as hsp65/ITS) gene sequencing to confirm as Mycobacterium chimaera species at https://cnphi. canada.ca/gts/reference-diagnostic-test/5054?labId=1004. Sending pure culture on solid or in a liquid (minimum 4mL) medium is optimal for the reference laboratory.
Isolates potentially tied to this outbreak are currently undergoing whole genome sequencing as part of a national collaborative effort. Results are pending. 
